Jan 27, 2021
Liminal BioSciences Provides Update on Business Strategy and Focus on Small Molecule Therapeutics
Jan 12, 2021
Liminal BioSciences Receives FDA Approval for its US-based Plasma Collection Center
Dec 15, 2020
Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras
Nov 13, 2020
Liminal Biosciences to Present at The Stifel Virtual Healthcare Conference
Nov 12, 2020
Liminal BioSciences Reports Third Quarter Financial Results
Nov 10, 2020
Liminal Biosciences to Reschedule Reporting of Q3 2020 Results and Conference Call
Nov 08, 2020
Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim®(plasminogen) BLA
Nov 06, 2020
Liminal Biosciences To Report Q3 2020 Results And Hold Conference Call
Nov 05, 2020
Liminal BioSciences Announces Upcoming Presentations for Ryplazim® (plasminogen) at the 62nd ASH Annual Meeting and Exposition
Oct 30, 2020
Liminal BioSciences Announces Private Placement Financing of USD$30 Million
Sep 09, 2020
Liminal BioSciences to Present at The H.C. Wainwright 22nd Annual Global Investment Conference
Sep 08, 2020
Liminal BioSciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen) for Treatment of Congenital Plasminogen Deficiency
Sep 01, 2020
Liminal BioSciences Announces New Appointments to its Board of Directors
Aug 10, 2020
Liminal BioSciences reports financial results for Q2-2020
Aug 06, 2020
Liminal Biosciences to Present at Canaccord 40th Annual Growth Conference
Jul 22, 2020
Liminal BioSciences to Voluntarily Delist from the Toronto Stock Exchange
Jul 17, 2020
Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases
Jul 02, 2020
Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy
Jun 30, 2020
Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors
Jun 30, 2020
Liminal BioSciences Provides Guidance Update on Certain Expected Key Milestones For 2020